MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
series b preferred...
$3,975,000
Proceeds from warrant
exercises
$2,572,067
Proceeds from warrant
inducement, net of issuance...
$2,200,012
Proceeds from public
offerings
$1,100,007
Net cash provided by
financing activities
$8,738,212
Canceled cashflow
$1,108,874
Increase in cash and cash
equivalents
$808,277
Canceled cashflow
$7,929,935
Transaction costs
associated with public...
$501,214
Transaction costs
associated with series b...
$391,376
Repayment of financed
insurance premiums
$216,284
Accounts payable
$1,815,658
Consultant compensation
$668,682
Accrued expenses and
other liabilities
$434,434
Stock-based compensation
$177,086
Accrued interest
$12,393
Depreciation expense
$6,533
Net cash used in
operating activities
-$7,806,292
Net cash flows used
in investing...
-$123,643
Canceled cashflow
$3,114,786
Net loss
-$10,176,187
Investment in property and
equipment
$123,643
Prepaid expenses and
other assets
$438,565
Unbilled receivable
$296,230
Change in fair value of
liability classified...
$10,096
Back
Back
Cash Flow
source: myfinsight.com
Ensysce Biosciences, Inc. (ENSC)
Ensysce Biosciences, Inc. (ENSC)